Investor Presentation
Investor Presentation
Brisbane, Oct 18, 2017 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

The presentation highlights the Company's key achievements and recent commercial activities:

- Current negotiations with #1 global animal health company, Zoetis Inc, regarding a commercial agreement for the worldwide development, distribution and marketing of Detach(R)

- Submission of the Company's dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach(R) for commercial marketing in Australia

- Preparing Detach(R) for commercial launch in the Australian market

- Revenue up 12.6% to $3.2 million, including the receipt of milestone payments under the Zoetis Research Evaluation and License Option Agreement, receipt of the 2015-16 R&D tax rebate and successful grant funding applications

The presentation also includes a status update on the Company's efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to human gastrointestinal conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease and Traveller's Diarrhoea.

To view the presentation, please visit:
http://abnnewswire.net/lnk/6F152097


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

    


Contact

Investor inquiries:
Dr Mel Bridges
Chairman & CEO
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anataralifesciences.com

Media inquiries:
Jane Lowe
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 12) (Last 30 Days: 89) (Since Published: 2841) 
ANALYTICS: LOGIN HERE

Anatara Lifesciences Ltd NEWS: RECENT VISITS (9988)

Research Report

Social Media